eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call.
Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.
Investors can pre-register now for the webinar HERE. The live webinar can also be accessed on the day of the event through eXoZymes' investor relations website at https://exozymes.com/investor#webinar
About eXoZymes
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature's own processes to produce chemical compounds, enabling the company's partners to replace traditional chemical production methods with a new sustainable, scalable, and eco-friendly alternative: Exozymes.
Exozymes are advanced enzymes enhanced with AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects. After SynBio, this pioneering technology enables entering the exozymes era of biotechnology.
While the company, eXoZymes Inc., has introduced "exozymes" (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
Investor relations contact
Email: [email protected]
eXoZymes media contact
Lasse Görlitz, VP of Communications
(858) 319-7135
[email protected]
